Akebia Therapeutics, Inc.
AKBA
Rank in Stocks
#18002
Akebia Therapeutics, Inc., established in 2007 and headquartered in Cambridge,... Akebia Therapeutics, Inc., established in 2007 and headquartered in Cambridge, Massachusetts, is a biopharmaceutical company focused on discovering and commercializing therapies for patients suffering from kidney diseases. The firm's leading experimental drug, vadadustat, is an oral treatment currently in Phase III clinical trials. Its purpose is to address anemia resulting from chronic kidney disease (CKD) in adult patients, encompassing both those dependent on dialysis and those who are not. Akebia also markets Auryxia, a ferric citrate product used to manage serum phosphorus levels in adult CKD patients undergoing dialysis, and to treat iron deficiency anemia in adult CKD patients who are not on dialysis. The company has several key collaboration agreements: with Otsuka Pharmaceutical Co. Ltd. for vadadustat's development and commercialization across major regions including the United States, European Union, Russia, China, Australia, Canada, and the Middle East; with Mitsubishi Tanabe Pharma Corporation for vadadustat in Japan and other Asian territories; and a research and licensing deal with Janssen Pharmaceutica NV pertaining to hypoxia-inducible factor prolyl hydroxylase targeted compounds globally.
Share Price
$0.5328
Last synced: 2026-11-09
Market Cap
$147.64M
Change (1 day)
32.77%
Change (1 year)
-70.56%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Akebia Therapeutics, Inc. (AKBA)
Category
Healthcare
EPS for Akebia Therapeutics, Inc. (AKBA)
EPS as of September 2026 TTM: $-0.16
According to Akebia Therapeutics, Inc.'s latest financial reports, its current EPS (TTM) is $-0.16. At the end of 2025 the company had an EPS of $-0.02, an increase over its 2024 EPS of $-0.33.
EPS history for Akebia Therapeutics, Inc. from 2012 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.16 | 700.00% |
| 2025 | $-0.02 | -93.70% |
| 2024 | $-0.33 | 17.86% |
| 2023 | $-0.28 | -51.72% |
| 2022 | $-0.58 | -60.81% |
| 2021 | $-1.48 | -41.50% |
| 2020 | $-2.53 | 7.20% |
| 2019 | $-2.36 | 60.54% |
| 2018 | $-1.47 | -16.95% |
| 2017 | $-1.77 | -50.83% |
| 2016 | $-3.60 | 57.21% |
| 2015 | $-2.29 | -4.58% |
| 2014 | $-2.40 | 252.94% |
| 2013 | $-0.68 | -16.05% |
| 2012 | $-0.81 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -9,887.50% |
US
|
|
| $-7.07 | 4,318.75% |
US
|
|
| $-5.29 | 3,206.25% |
AU
|
|
| $12.88 | -8,150.06% |
BE
|
|
| $21.56 | -13,575.00% |
NL
|
Questions about Akebia Therapeutics, Inc.'s earnings per share (EPS)
What is Akebia Therapeutics, Inc.'s earnings per share (EPS)?
Akebia Therapeutics, Inc.'s earnings per share (EPS) over the last twelve months is $-0.16, as of Sep 2026.
What was Akebia Therapeutics, Inc.'s earnings per share (EPS) in 2025?
In 2025, Akebia Therapeutics, Inc.'s earnings per share (EPS) was $-0.02, compared with $-0.33 in 2024.
How has Akebia Therapeutics, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Akebia Therapeutics, Inc.'s earnings per share (EPS) was highest in 2025 ($-0.02) and lowest in 2020 ($-2.53).
How does Akebia Therapeutics, Inc.'s earnings per share (EPS) compare with similar companies?
Akebia Therapeutics, Inc.'s earnings per share (EPS) ($-0.16) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.